Fund Higher Ed Now

Reductil Sibutramina is a drug approved by the FDA in early 1999 for the long-term treatment of obesity. Its use is limited to patients with one BMI greater than 30 or higher to 27 when they have complications such as diabetes and/or Dyslipidemia. Presented as a suppressor not stimulants of appetite, sibutramine is not a substitute for diet therapy, but that comes to be one of the four pillars upon which the anti-obesity treatment must be installed. I.e., to treat an obese patient from the characteristics mentioned above, it is necessary to induce a change in lifestyle, carry out a hypocaloric diet, increase physical activity and underpin this effort with appropriate drugs. For assistance, try visiting Healthy Living. Sibutramine acts by inhibiting the reuptake of serotonin, dopamine and norepinephrine via its two active metabolites, thus causing a prolonged on the satiety Centre stimulus, decreasing the appetite of the treated patient, and generating shaped paralelela an increase in energy expenditure. Both active metabolites show an average life of 15 hours, so the action of a compressed has a duration of one day about (1 tablet per day). Along with the weight loss observed in the treatment with sibutramine, improvements in glucose tolerance curve, found in the levels of uric acid and lipid profile of the patient, noting a decrease in serum levels of LDL cholesterol, total cholesterol and triglycerides and a concomitant increase in HDL cholesterol. This drug is supplied in 10 or 15 mg/day dose. Learn more about this with cerebral palsy. Since adverse effects, if well mostly mild, are higher in the first four weeks, we recommend starting with 10 mg/day.